Last reviewed 2026-04-23 · How we verify

OraVerse Injectable Product

sara nabil · Phase 3 active Small molecule

OraVerse Injectable Product is a Alpha-adrenergic antagonist Small molecule drug developed by sara nabil. It is currently in Phase 3 development for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures.

OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors.

OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors. Used for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OraVerse Injectable Product
Sponsor	sara nabil
Drug class	Alpha-adrenergic antagonist
Target	Alpha-1 and alpha-2 adrenergic receptors
Modality	Small molecule
Therapeutic area	Dental/Local Anesthesia
Phase	Phase 3

Mechanism of action

OraVerse works as a non-selective alpha-adrenergic antagonist that competitively blocks the effects of epinephrine and norepinephrine used in local anesthetic formulations. By antagonizing alpha-1 and alpha-2 adrenergic receptors in the vasculature, it promotes vasodilation and accelerates the resorption and clearance of the vasoconstrictor, thereby reducing the duration of local anesthesia-induced numbness and hemostasis.

Approved indications

Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures

Common side effects

Tachycardia
Tremor
Headache
Palpitations

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OraVerse Injectable Product CI brief — competitive landscape report
OraVerse Injectable Product updates RSS · CI watch RSS
sara nabil portfolio CI

Frequently asked questions about OraVerse Injectable Product

What is OraVerse Injectable Product?

OraVerse Injectable Product is a Alpha-adrenergic antagonist drug developed by sara nabil, indicated for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures.

How does OraVerse Injectable Product work?

OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors.

What is OraVerse Injectable Product used for?

OraVerse Injectable Product is indicated for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures.

Who makes OraVerse Injectable Product?

OraVerse Injectable Product is developed by sara nabil (see full sara nabil pipeline at /company/sara-nabil).

What drug class is OraVerse Injectable Product in?

OraVerse Injectable Product belongs to the Alpha-adrenergic antagonist class. See all Alpha-adrenergic antagonist drugs at /class/alpha-adrenergic-antagonist.

What development phase is OraVerse Injectable Product in?

OraVerse Injectable Product is in Phase 3.

What are the side effects of OraVerse Injectable Product?

Common side effects of OraVerse Injectable Product include Tachycardia, Tremor, Headache, Palpitations.

What does OraVerse Injectable Product target?

OraVerse Injectable Product targets Alpha-1 and alpha-2 adrenergic receptors and is a Alpha-adrenergic antagonist.

Drug class: All Alpha-adrenergic antagonist drugs
Target: All drugs targeting Alpha-1 and alpha-2 adrenergic receptors
Manufacturer: sara nabil — full pipeline
Therapeutic area: All drugs in Dental/Local Anesthesia
Indication: Drugs for Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing